Brain Cancer

Dabrafenib plus trametinib exhibited encouraging activity among patients with recurrent or refractory BRAF V600E mutation-positive glioma, according to study results.

Morning administration of temozolomide appeared associated with longer OS compared with evening administration among patients with newly diagnosed glioblastoma, according to study results published in Neuro-Oncology Advances.

Michael E. Salacz, MD, has been appointed director of the neuro-oncology program at Rutgers Cancer Institute of New Jersey.

OKN-007 received FDA fast track designation for the treatment of children with diffuse intrinsic pontine glioma, or DIPG, according to a press release from the agent’s manufacturer.

The FDA granted fast track designation to GLR2007 for treatment of glioblastoma, according to the agent’s manufacturer.

Manmeet Ahluwalia, MD, FACP, MBA, has been appointed deputy director of Baptist Health’s Miami Cancer Institute.

The FDA granted orphan drug designation to aminolevulinic acid hydrochloride, an optical imaging agent that helps visualize tumor tissue during resection of meningioma, according to a manufacturer-issued press release.

Toxoplasma gondii infection appeared to increase the risk for glioma in adults, according to study results published in International Journal of Cancer.

Low-grade glioma is a historically challenging cancer to treat, with some patients succumbing to the disease within weeks of diagnosis and others surviving for decades.

Stereotactic radiosurgery conferred equivalent OS as whole-brain radiation but with less cognitive decline in patients with four or more nonmelanoma brain metastases, according to study results presented at the virtual ASTRO Annual Meeting.